Carbetocin

Ferring's total revenues for 2025 exceeded €2.5 billion, an increase of 10% from 2024, mainly driven by our flagship product Menopur ® Continued ramp-up in the US for Adstiladrin ® , our novel gene-based therapy for bladder cancer, confirming its position as Ferring’s second major growth driver Commitment to sustainability demonstrated by SBTi approval of our targets to reduce greenhouse gas emissions, and by our programme to reduce maternal deaths in low- and lower middle-income countries SAINT-PREX, Switzerland--(BUSINESS WIRE)--Ferring today published its 2025 Annual Report and Sustainability Report . The company achieved total revenues of over €2.5 billion in 2025, an increase of 7% over the previous year at actual exchange rates (AER) and 10% at constant exchange rates (CER). These were mainly driven by our flagship product Menopur ® (menotropins for injection) in reproductive medicine, and the ramp-up in the US of our breakthrough gene-based therapy for non-muscle invasive bladder cancer, Adstiladrin ® (nadofaragene firadenovec-vncg). Operating expenses were contained to an increase of €61 million year-on-year (i.e. +5% at AER and +7% at CER), and this includes significant non-recurring items (notably impairment charges and restructuring provisions). Underlying operating expenses remained well-controlled, with increased investments targeted to support the growth of Adstiladrin and other opportunities. Thus, operating profit for the year reached €167 million, a decrease of -€24 million (‑13%) versus the prior year at AER, while remaining flat at CER - with the difference being driven by the weaker US dollar. Following a focus on improving cash conversion after several heavy investments, free cash flow generation approached neutral despite currency headwinds from the weaker US dollar. This represents a substantial improvement compared to the previous year, and a significant step towards sustainable cash generation. Jean-Frédéric Paulsen, Chairman of the Board of Directors and Chief Executive Officer, said: “This was a pivotal year as we continued evolving our business to become stronger, more agile and more resilient, and importantly we got back to free cash flow neutral. Moreover, in 2025, we introduced an enterprise model designed to create greater value for patients and customers while supporting sustainable growth. This reflects our long-term commitment to serving patients’ need, and fostering an environment where people can learn, grow and perform at their best.” Ferring has always conducted business responsibly by seeking to protect the environment, create value for society, and uphold our high standards of ethics and governance. In 2025, we passed a major milestone when our targets for reducing greenhouse gas (GHG) emissions were approved by the Science Based Targets initiative (SBTi). This globally recognised standard ensures corporate goals are aligned with international climate policy. During the year, we succeeded in reducing our Scope 1 and 2 GHG emissions by 4.3% and Scope 3 emissions by 19%. Access to affordable healthcare is embedded in Ferring’s purpose and strategic priorities. The Project Family™: Safe Birth initiative aims to reduce maternal deaths in low- and lower middle-income countries by enabling wider access to Carbetocin Ferring (carbetocin, room-temperature stable formulation). In 2025, we worked with partners to supply around 1.7 million doses of this life-saving medicine at an affordable access price, while gaining further approvals in seven low- and lower middle-income countries. About Ferring Pharmaceuticals Ferring Pharmaceuticals is a privately owned specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine with a strong heritage in gastroenterology and urology and are at the forefront of innovation in uro-oncology gene therapy. Ferring was founded in 1950 and employs more than 7,500 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which market its medicines in over 100 countries. Learn more at , or connect with us on LinkedIn , Instagram and YouTube . Contacts For more information, please contact Carine Julen Senior Manager, Corporate Communications & Public Affairs carine.julen@ferring.com

BASEL, Switzerland, Dec. 18, 2025 /PRNewswire/ -- Postpartum haemorrhage (PPH), is the leading cause of maternal death in Sub-Saharan Africa. Standard care in these settings often relies on visual estimates of blood loss, which frequently underestimates severity and delays critical interventions. Continue Reading Health worker at the Presbyterian Health Center in Fooshegu, Northern Ghana Carbetocin on the shelf of a health center inventory room, supplied by Axmed A ground-breaking study demonstrated that early PPH detection using a calibrated obstetric drape combined with a bundle of first-response treatments reduced severe PPH and maternal death by 60%. Now, a new partnership announced today between LifeNet International and Axmed is bringing these breakthrough findings to the frontlines, equipping health facilities with calibrated drapes, treatment training, heat-stable carbetocin and other critical supplies that enable safe deliveries This collaboration is already delivering tangible results on the ground, exemplifying the impact of improved access to essential health products. The Presbyterian Health Center in Fooshegu, Northern Ghana, a rural clinic that delivers over 120 newborns each month, is now equipped with heat-stable carbetocin, calibrated drapes, and other critical supplies. The clinic has recorded zero maternal deaths in recent months, a testament to the work LifeNet and Axmed are doing to drastically improve the chance for a healthy start to life for delivering mothers and babies throughout Ghana. "Our partnership with Axmed is an excellent example of the way LifeNet is utilizing larger networks to increase access to compassionate and equitable healthcare. Through our collaboration with Axmed, we have a greater impact on improving maternal and child health outcomes and ending preventable deaths in some of Africa's most under-resourced communities," said Santiago Sedaca, CEO of LifeNet International. The partnership spans both organizations' network and footprint across Africa, combining Axmed's innovative procurement platform with LifeNet's capacity building expertise. Together they are reaching health facilities in underserved regions wherever gaps in access to quality healthcare exist. "LifeNet and Axmed share a conviction that access to essential care is a right, not determined by geography. Through our partnership, clinics are already receiving the medicines they need to deliver life-saving care to mothers and newborns. MNCH is our proof of concept, and we're using technology to scale this across diseases, turning access from a promise into a functioning system," said Felix Ohnmacht, Co-Founder of Axmed. About Axmed: Axmed is a technology-enabled marketplace transforming how medicines and health products are sourced, financed, procured, and delivered across low- and middle-income countries. By digitizing large-scale procurement and aggregating demand, Axmed enables direct access to a trusted network of prequalified local and international suppliers. Learn more at About LifeNet International: LifeNet International is a cross-continent network of local, faith-based health facilities in Africa. LifeNet's professional training, delivered on-site, bridges the gap between existing knowledge and resources and the health workers who need them to save lives. Through its growing network of over 500 facilities, LifeNet transforms healthcare for more than 12 million patient visits every year and saves the lives of over 6,000 mothers and babies annually. Learn more at lninternational.org Media Inquiries: [email protected] or [email protected] Photo - Photo - SOURCE Axmed; LifeNet International 21% more press release views with Request a Demo